1. Lyman, GH, Kuderer, NM. Epidemiology of febrile neutropenia. Supportive Cancer Therapy 2003; 1: 23–35.
Google Scholar | Crossref | Medline2. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute . Common terminology criteria for adverse events (CTCAE), evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/Archive/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf (accessed 11 July 2020).
Google Scholar3. Bodey, GP, Buckley, M, et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64(2): 328–340.
Google Scholar | Crossref | Medline | ISI4. Green, MD, Koelbl, H, Baselga, J, et al. A randomized double-blind multicenter phase III study of fixed dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003; 14: 29–35.
Google Scholar | Crossref | Medline | ISI5. National Institute for Health Care Excellence . Neutropenic sepsis: prevention and management of neutropenic sepsis in cancer patients. CG151. London: NICE, 2012, www.nice.org.uk/guidance/cg151/ (accessed 11 July 2020).
Google Scholar6. Klastersky, J. Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis 2004; 39(Suppl. 1): S32–S37.
Google Scholar | Crossref | Medline7. Kuderer, NM, Dale, DC, Crawford, J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006; 106: 2258–2266.
Google Scholar | Crossref | Medline | ISI8. Bow, EJ. Neutropenic fever syndromes in patients undergoing cytotoxic therapy for acute leukemia and myelodysplastic syndromes. Semin Hematol 2009; 46(3): 259–268.
Google Scholar | Crossref | Medline9. Singer, M, Deutschman, CS, Seymour, CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016; 315: 801–810.
Google Scholar | Crossref | Medline | ISI10. Lyman, GH, Lyman, C, Ogboola, Y. Risk models for the prediction of chemotherapy-induced neutropenia. Neutropenia Oncol 2001; 1: 2–7.
Google Scholar11. Klastersky, J, Paesmans, M, Rubenstein, EB, et al. The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18(16): 3038–3051.
Google Scholar | Crossref | Medline | ISI12. COC(Medicine) Hospital Authority . Handbook of Internal Medicine 8th edition 2019.
Google Scholar13. Karimi, F, Ashrafi, F, Moghaddas, A, et al. Management of febrile neutropenia: a description of clinical and microbiological findings by focusing on risk factors and pitfalls. J Res Pharm Pract 2018; 7(3): 147–156.
Google Scholar | Crossref | Medline14. Lyman, GH, Lyman, CH, Agboola, O. Risk models for predicting chemotherapy-induced neutropenia. Oncologist 2005; 10(6): 427–437.
Google Scholar | Crossref | Medline | ISI15. Lyman, GH, Dale, DC, Friedberg, J, et al. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin’s lymphoma: a nationwide study. J Clin Oncol 2004; 22: 4302.
Google Scholar | Crossref | Medline | ISI16. Renehan, AG, Yeh, HC, Johnson, JA, et al. Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer. Diabetologia 2012; 55(6): 1619–1632.
Google Scholar | Crossref | Medline17. Ray-Coquard, I, Borg, C, Bachelot, T, et al. Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy. Br J Cancer 2003; 88: 181.
Google Scholar | Crossref | Medline18. Bow, EJ. Infectious complications in patients receiving cytotoxic therapy for acute leukemia: History, background, and approaches to management. In: Wingard, JR, Bowden, RA (eds) Management of Infection in Oncology Patients. London: Martin Dunitz, 2003, p. 71.
Google Scholar | Crossref19. Aapro, MS, Cameron, DA, Pettengell, R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006; 42(15): 2433–2453.
Google Scholar | Crossref | Medline | ISI20. International Society of Nurses in Cancer Care (ISNCC) Blog . Prompt antibiotics for neutropenic fever: no more excuse, news.isncc.org/prompt-antibiotics-for-neutropenic-fever-no-more-excuse/ (accessed 16 July 2020).
Google Scholar21. HA Convention 2017 . Session service enhancement presentation 3. Clinical safety and quality service I: Streamline care pathway for cancer patients at risk of febrile neutropenia after chemotherapy treatment.
Google Scholar22. Ying, FLM, Ping, MCY, Tong, M, et al. A cohort study on protocol-based nurse-led out-patient management of post-chemotherapy low-risk febrile neutropenia. Support Care Cancer 2018; 26(9): 3039–3045.
Google Scholar | Crossref | Medline